Emcure Pharmaceuticals is currently trading at Rs. 1452.40, up by 6.50 points or 0.45% from its previous closing of Rs. 1445.90 on the BSE.

The scrip opened at Rs. 1401.65 and has touched a high and low of Rs. 1463.45 and Rs. 1401.65 respectively. So far 319 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1585.50 on 19-Jan-2026 and a 52 week low of Rs. 890.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1488.95 and Rs. 1390.00 respectively. The current market cap of the company is Rs. 27410.29 crore.

The promoters holding in the company stood at 77.87%, while Institutions and Non-Institutions held 9.69% and 12.44% respectively.

Emcure Pharmaceuticals has signed a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. The agreement marks a significant step toward expanding patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India. Under the agreement, which will be effective April 1, 2026, Emcure will distribute Roche’s established and globally recognised brands in the nephrology and transplant segment in India.

Emcure is a market leader in anemia management, and together with its subsidiaries, has a strong presence across nephrology and chronic kidney disease segments. Roche’s nephrology and transplant portfolio strongly complements Emcure’s existing offerings. This strategic alignment enables Emcure to expand its portfolio and bring these important medicines to a wider cross-section of patients across the country. 

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.